The U.S. Supreme Court may soon revisit one of its seminal decisions defining products liability law for pharmaceutical manufacturers. That decision — Wyeth v. Levine — addressed whether a branded manufacturer could be held liable for statelaw failure-to-warn claims even though federal law regulates the contents of its drug’s label.
Lower courts have struggled to apply Levine’s "clear evidence" standard, and the Third Circuit, in In re: Fosamax, arguably gutted it altogether. Merck & Co.’s petition for a writ of certiorari in In re: Fosamax is pending before the Supreme Court, where it awaits the views of the Solicitor General. If the Supreme Court grants certiorari, it could signal that In re: Fosamax will be overturned and lower courts (as well as branded manufacturers) will finally receive guidance on Levine’s “clear evidence” standard.
Originally published in Law360 on March 8, 2018.
Please see full publication below for more information.